Significant improvements in clinical remission rates were seen with risankizumab compared to placebo in patients with ulcerative colitis. The phase 3 INSPIRE and COMMAND trials showed that Skyrizi, a monoclonal antibody targeting the IL-23 p19 subunit, resulted in better clinical remission rates as both induction and maintenance therapy. Results from the trials demonstrated that risankizumab significantly improved rates of clinical remission at 12 weeks and 52 weeks compared to placebo. The researchers noted no adverse event signals among treatment groups and suggested further study to identify benefits beyond the 52-week follow-up.
Source link
Skyrizi bests placebo in clinical remission as induction, maintenance therapy for UC
